What drove ALTME.PA stock higher today?

ALTME.PA stock rose intraday on heavy volume, likely driven by renewed attention to its NOX-A12 clinical collaborations and short-term technical breakout above the 50-day average.

What is Meyka AI's rating for ALTME.PA stock?

Meyka AI rates ALTME.PA **61.42/100** (Grade B) with a **HOLD** suggestion. The grade factors in benchmark and sector comparisons, key metrics, financial growth and analyst inputs.

What price targets exist for ALTME.PA stock?

Meyka AI's model projects a quarterly target of **EUR 0.10** and a 12-month model target of **EUR 0.2578833364**, implying **+237.09%** versus the current price of **EUR 0.0765**. Forecasts are not guarantees.

How risky is trading ALTME.PA stock?

ALTME.PA stock is high risk: negative earnings, tight cash per share, and clinical binary events dominate valuation. Intraday liquidity can spike, increasing volatility and gap risk.

EU Stocks

ALTME.PA stock +15.91% intraday on EURONEXT: momentum opens short-term targets

ByDanny Kontos January 30, 2026January 30, 2026

TME Pharma N.V. (ALTME.PA) on EURONEXT jumped 15.91% intraday to trade at EUR 0.0765, making it one of today’s top gainers in Europe. ALTME.PA stock rallied on heavy volume of 1,394,001 shares versus an average of 253,930, focusing trader attention on clinical collaborations and short-term technical breakouts. We review what moved the tape, the company’s fundamentals, and how market structure and forecasts shape near-term price targets.